| 翻訳と辞書 |
| David L. Hallal ： ウィキペディア英語版 |
David L. Hallal
David L. Hallal is the President and Chief Executive Officer (CEO) of Alexion Pharmaceuticals, the American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).〔(【引用サイトリンク】title=Alexion Submits Application for Soliris )〕〔(【引用サイトリンク】title=Alexion Pharmaceuticals on the Forbes World’s Most Innovative Companies List )〕
==Career at Amgen==
(詳細はbiotechnology firm. While at Amgen, Hallal focused on Amgen's blockbuster brands Epoetin alfa (brand name Epogen) and Filgrastim (brand name Neupogen), Pegfilgrastim (brand name Neulasta) and Darbepoetin alfa (brand name Aranesp) in the hematology and oncology marketplace, in various escalating leadership positions.〔 During that time he forged "relationships with many of the largest managed care organizations in the U.S."〔 Then as Amgen's Director of Oncology National Accounts in 1998 and 1999 he "played a significant role in developing key long-term partnerships with the nation's largest oncology practice management groups and physician group purchasing organizations."〔
From 1999 to 2002, he was Sales Director of Southeast Oncology during which time he helped Amgen build its first dedicated hospital sales team. 〔
By 2006 Amgen's Epogen and Aranesp—Epogen's longer-lasting version also known as Darbepoetin alfa (rINN), a synthetic form of erythropoietin— "combined generated an annual worldwide sales of $6.6 billion.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「David L. Hallal」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|